Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Objective. The diagnostic value of antinuclear antibodies (ANAs) including anti-gp210 and anti-sp100 for primary biliary cholangitis/cirrhosis (PBC) has been widely reported. However, their diagnostic performances for antimitochondrial antibody- (AMA-) negative PBC were less well elucidated. Therefore, the aim of the current meta-analysis was to evaluate the diagnostic accuracy of ANAs in patients with AMA-negative PBC.Materials and Methods. Literature on the diagnostic value of biomarkers for AMA-negative PBC was systematically searched in PubMed, MEDLINE, EMBASE, and the Cochrane Library. The qualities of the retrieved studies were assessed by the Quality Assessment of Diagnostic Accuracy Studies-version 2 (QUADAS-2) scale. Pooled sensitivity and specificity of the biomarkers were calculated with random-effects models. The areas under the summary receiver operating characteristic (AUSROC) curves were used to evaluate the overall diagnostic performance of ANAs.Results. A total of 11 studies (400 AMA-negative PBC patients and 6217 controls) were finally included in the meta-analysis. ANAs had an overall sensitivity of 27% (95% CI: 20%, 35%) and specificity of 98% (95% CI: 97%, 99%). The pooled sensitivities for anti-gp210 and anti-sp100 were 23% (95% CI: 13%, 37%) and 25% (95% CI: 13%, 43%), respectively, and their specificities were 99% (95% CI: 97%, 100%) and 97% (95% CI: 93%, 98%), respectively.Conclusions. ANAs exhibited high specificity but low sensitivity and therefore could be used as reliable biomarkers to reduce the necessity of liver histology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Both anti-gp210 and anti-sp100 show low sensitivities (23% for anti-gp210 and 25% for anti-sp100), but high specificity (over 95%) for anti-mitochondrial antibody-negative primary biliary cholangitis.53”
From Primary biliary cholangitis. (2024) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Deeks, J. J., Macaskill, P., & Irwig, L. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.016 · Cited by 2,910 · cited 1×
“Deeks’ test was used to detect funnel plot asymmetry in reviews of diagnostic studies to investigate publication bias [22].”
MethodHirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · cited 2×
“According to major international guidelines, the diagnosis of PBC can be confidently made in patients with clinical, biochemical, and radiological evidence of intrahepatic cholestasis if they are positive for AMA [3, 4].”
BackgroundLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · cited 4×
“This is especially relevant for patients with high suspicion of PBC but negative for AMA and probably could reduce the necessity of liver histology in this setting [3].”
BackgroundInfluentialCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Management of primary biliary cirrhosis
Heathcote, J. E. (2000) · Hepatology · doi:10.1053/he.2000.5984 · Cited by 417
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Cochrane diagnostic test accuracy reviews
Leeflang, M. M., Deeks, J. J., Takwoingi, Y., & Macaskill, P. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-82 · Cited by 292
Szostecki, C., Guldner, H. H., Netter, H. J., & Will, H. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.12.4338 · Cited by 269
Greber, U. F., Senior, A., & Gerace, L. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08267.x · Cited by 218
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis
Muratori, P., Muratori, L., Ferrari, R., Cassani, F., Bianchi, G., Lenzi, M., Rodrigo, L., Linares, A., Fuentes, D., & Bianchi, F. B. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07257.x · Cited by 204 · cited 1×
“It is justified to evaluate the diagnostic accuracy of ANAs in patients with high suspicion of PBC but negative for AMA, with the aim to reduce the necessity of liver biopsy which is invasive in nature and potentially causes serious complications [16, 17].”
BackgroundCorrelation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
Wesierska-Gadek, J., Penner, E., Battezzati, P. M., Selmi, C., Zuin, M., Hitchman, E., Worman, H. J., Gershwin, E. M., Podda, M., & Invernizzi, P. (2006) · Hepatology · doi:10.1002/hep.21172 · Cited by 177
The diagnosis of primary biliary cirrhosis
Bowlus, C. L., & Gershwin, M. E. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.041 · Cited by 162
Nakamura, M., Shimizu‐Yoshida, Y., Takii, Y., Komori, A., Yokoyama, T., Ueki, T., Daikoku, M., Yano, K., Matsumoto, T., Migita, K., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.016 · Cited by 136
Rigopoulou, E. I., Davies, E. T., Pares, A., Zachou, K., Liaskos, C., Bogdanos, D.-P., Rodes, J., Dalekos, G. N., & Vergani, D. (2005) · Gut · doi:10.1136/gut.2003.036558 · Cited by 134
Cirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 124
Nuclear Dot Antigens may Specify Transcriptional Domains in the Nucleus
Xie, K., Lambie, E. J., & Snyder, M. P. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6170-6179.1993 · Cited by 88
Anti‐kelch‐like 12 and anti‐hexokinase 1: novel autoantibodies in primary biliary cirrhosis
Norman, G. L., Yang, C., Ostendorff, H. P., Shums, Z., Lim, M. J., Wang, J., Awad, A., Hirschfield, G. M., Milkiewicz, P., Bloch, D. B., et al. (2015) · Liver International · doi:10.1111/liv.12690 · Cited by 87
PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis
Granito, A., Yang, W.-H., Muratori, L., Lim, M. J., Nakajima, A., Ferri, S., Pappas, G., Quarneti, C., Bianchi, F. B., Bloch, D. B., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.596 · Cited by 82
Bizzaro, N., Covini, G., Rosina, F., Muratori, P., Tonutti, E., Villalta, D., Pesente, F., Alessio, M. G., Tampoia, M., Antico, A., et al. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8234-y · Cited by 79
GRANITO, A., MURATORI, P., MURATORI, L., PAPPAS, G., CASSANI, F., WORTHINGTON, J., GUIDI, M., FERRI, S., DE MOLO, C., LENZI, M., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03172.x · Cited by 79
Ursodeoxycholic acid treatment of vanishing bile duct syndromes
Pusl, T. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i22.3487 · Cited by 76
Invernizzi, P., Battezzati, P. M., Crosignani, A., Zermiani, P., Bignotto, M., Del Papa, N., Zuin, M., & Podda, M. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1998.00735.x · Cited by 70
Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis
Nakamura, M. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1383732 · Cited by 69
Yamagiwa, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2606 · Cited by 65
Tanaka, A., Ma, X., Yokosuka, O., Weltman, M., You, H., Amarapurkar, D. N., Kim, Y. J., Abbas, Z., Payawal, D. A., Chang, M.-L., et al. (2016) · Hepatology International · doi:10.1007/s12072-016-9767-9 · Cited by 55
Self-citationde Liso, F., Matinato, C., Ronchi, M., & Maiavacca, R. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0249 · Cited by 54
Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease
Milkiewicz, P., Buwaneswaran, H., Coltescu, C., Shums, Z., Norman, G. L., & Heathcote, E. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.012 · Cited by 52
Antimitochondrial antibody‐negative primary biliary cirrhosis: a subset of primary biliary cirrhosis
Liu, B., Shi, X. H., Zhang, F. C., Zhang, W., & Gao, L. X. (2008) · Liver International · doi:10.1111/j.1478-3231.2007.01651.x · Cited by 49
Autoantibodies and Liver Disease: Uses and Abuses
Zeman, M. V., & Hirschfield, G. M. (2010) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2010/431913 · Cited by 47
Diagnosis and Management of Overlap Syndromes
Bunchorntavakul, C., & Reddy, K. R. (2014) · Clinics in Liver Disease · doi:10.1016/j.cld.2014.09.005 · Cited by 44
Diagnosis of primary biliary cirrhosis
Hirschfield, G. M. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.10.005 · Cited by 43
Ursodeoxycholic Acid Treatment of Vanishing Bile Duct Syndromes
Rust, C., & Beuers, U. (2020) · The Pathophysiology of Biliary Epithelia · doi:10.1201/9780367813888-33 · Cited by 42
The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis
Özaslan, E., Efe, C., & ÖZASLAN, N. G. (2016) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.06.001 · Cited by 41
Meta-Analysis Assessment of GP210 and SP100 for the Diagnosis of Primary Biliary Cirrhosis
Hu, S.-L., Zhao, F.-R., Hu, Q., & Chen, W.-X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101916 · Cited by 40
AUTOANTIBODIES BY LINE IMMUNOASSAY IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
Saito, H., Takahashi, A., Abe, K., Okai, K., Katsushima, F., Monoe, K., Kanno, Y., & Ohira, H. (2012) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.58.107 · Cited by 39
Hu, C., Deng, C., Song, G., Zhang, W., Zhang, S., Li, X., Li, P., Zhang, F., & Li, Y. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1756-1 · Cited by 33
Comay, D., Cauch‐Dudek, K., Hemphill, D., Diamandis, E. P., Wanless, I. R., & Heathcote, E. J. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005548126211 · Cited by 24
Remmel, T., Piirsoo, A., Kǒiveer, A., Remmel, H., Uibo, R., & Salupere, V. (1996) · PubMed · Cited by 22
[Diagnostic significance of autoantibodies in patients with primary biliary cirrhosis].
Xiao, H., Chen, J., Xie, X. S., Liu, Y.-M., & Li, F. (2012) · PubMed · Cited by 11
[Clinicopathologic features of drug-induced vanishing bile duct syndrome].
Ye, L., Wang, C. K., Zhang, H. C., Liu, Z., & Zheng, H. (2017) · PubMed · doi:10.3760/cma.j.issn.1007-3418.2017.04.019 · Cited by 5
Self-citation
Research works printed but not linked: 3
- 10.1128/mcb.13.10.6170 · DOI
- 2012, Journal of Peking University (Health sciences), 44, 209
- 1996, Hepatogastroenterology, 43, 1135
Cited by
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133
Self-citationGuidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)
You, H., Duan, W., Li, S., Lv, T., Chen, S., Lu, L., Ma, X., Han, Y., Nan, Y., Xu, X., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00347 · Cited by 46
Self-citationVillalta, D., Seaman, A., Tiongson, M., Warren, C., Bentow, C., Bizzaro, N., Alessio, M. G., Porcelli, B., Norman, G. L., & Mähler, M. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0122 · Cited by 28
Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis
Bauer, A., & Habior, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885229 · Cited by 25
Metadata
- Authors
- Zhang, Q., Liu, Z., Wu, S., Duan, W., Chen, S., Ou, X., You, H., Kong, Y., & Jia, J.
- Affiliations
- Capital Medical University (CN)
- Fujian Medical University (CN)
- Corresponding author
- Kong, Yuanyuan
- Jia, Jidong
- Venue
- Gastroenterology Research and Practice
- Publisher
- Wiley
- Published
- 2019-06-10
- Volume
- 2019
- Pages
- 1-12
- ISSN
- 1687-6121 (ISSN-L)
- 1687-630X
- PMC
- PMC6590611
- OpenAlex
- W2952950257
- Cited by
- 28
- References
- 42
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 4
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Gastroenterology Research and Practice (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science and Technology Major Special Project for Infectious Diseases (2018ZX10302204, 2018ZX09201016, XXZ0203, XXX0104)
- National Science and Technology Major Special Project for New Drug Development (2018ZX10302204, 2018ZX09201016, XXZ0203, XXX0104)
- Beijing Municipal Administration of Hospitals (2018ZX10302204, 2018ZX09201016, XXZ0203, XXX0104)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- antinuclear antibodies, primary biliary cirrhosis, diagnostic accuracy, sensitivity and specificity, biomarkers, liver histopathology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.